These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 33590389)

  • 41. Acid reflux directly causes sleep disturbances in rat with chronic esophagitis.
    Nakahara K; Fujiwara Y; Tsukahara T; Yamagami H; Tanigawa T; Shiba M; Tominaga K; Watanabe T; Urade Y; Arakawa T
    PLoS One; 2014; 9(9):e106969. PubMed ID: 25215524
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Esophageal mucosal breaks in gastroesophageal reflux disease partially responsive to proton pump inhibitor therapy.
    Shaheen NJ; Denison H; Björck K; Silberg DG
    Am J Gastroenterol; 2013 Apr; 108(4):529-34. PubMed ID: 23318482
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Medical treatments of reflux esophagitis - Proton pump inhibitors and histamine H2 receptor antagonists -].
    Kinoshita Y; Ishimura N
    Nihon Rinsho; 2016 Aug; 74(8):1304-1310. PubMed ID: 30562433
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Randomized controlled trial of transoral incisionless fundoplication vs. proton pump inhibitors for treatment of gastroesophageal reflux disease.
    Witteman BP; Conchillo JM; Rinsma NF; Betzel B; Peeters A; Koek GH; Stassen LP; Bouvy ND
    Am J Gastroenterol; 2015 Apr; 110(4):531-42. PubMed ID: 25823768
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Increased acid and bile reflux in Barrett's esophagus compared to reflux esophagitis, and effect of proton pump inhibitor therapy.
    Menges M; Müller M; Zeitz M
    Am J Gastroenterol; 2001 Feb; 96(2):331-7. PubMed ID: 11232672
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Proton Pump Inhibitors in Gastroesophageal Reflux Disease: Friend or Foe.
    Gyawali CP
    Curr Gastroenterol Rep; 2017 Sep; 19(9):46. PubMed ID: 28780717
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [Pathophysiology and treatment of reflux esophagitis].
    Iwakiri K; Kawami N
    Nihon Rinsho; 2015 Jul; 73(7):1098-102. PubMed ID: 26165064
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Predictors of proton pump inhibitor failure in non-erosive reflux disease: A study with impedance-pH monitoring and high-resolution manometry.
    Shi Y; Tan N; Zhang N; Xiong L; Peng S; Lin J; Chen M; Xiao Y
    Neurogastroenterol Motil; 2016 May; 28(5):674-9. PubMed ID: 26768192
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Helicobacter pylori infection correlates with severity of reflux esophagitis: with manometry findings.
    Shirota T; Kusano M; Kawamura O; Horikoshi T; Mori M; Sekiguchi T
    J Gastroenterol; 1999 Oct; 34(5):553-9. PubMed ID: 10535481
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Association of erosive esophagitis with Helicobacter pylori eradication: a role of salivary bicarbonate and glycoprotein secretion.
    Namiot DB; Namiot Z; Markowski AR; Leszczyńska K; Bucki R; Kemona A; Gołebiewska M
    Dis Esophagus; 2009; 22(4):368-73. PubMed ID: 19222537
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Esophageal pH-impedance monitoring in patients with therapy-resistant reflux symptoms: 'on' or 'off' proton pump inhibitor?
    Hemmink GJ; Bredenoord AJ; Weusten BL; Monkelbaan JF; Timmer R; Smout AJ
    Am J Gastroenterol; 2008 Oct; 103(10):2446-53. PubMed ID: 18684197
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Overlap of reflux and eosinophilic esophagitis in two patients requiring different therapies: a review of the literature.
    Molina-Infante J; Ferrando-Lamana L; Mateos-Rodríguez JM; Pérez-Gallardo B; Prieto-Bermejo AB
    World J Gastroenterol; 2008 Mar; 14(9):1463-6. PubMed ID: 18322968
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Lack of improvement of impaired chemical clearance characterizes PPI-refractory reflux-related heartburn.
    Frazzoni M; Frazzoni L; Tolone S; De Bortoli N; Savarino V; Savarino E
    Am J Gastroenterol; 2018 May; 113(5):670-676. PubMed ID: 29681623
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Adding Acotiamide to Gastric Acid Inhibitors Is Effective for Treating Refractory Symptoms in Patients with Non-erosive Reflux Disease.
    Yamashita H; Okada A; Naora K; Hongoh M; Kinoshita Y
    Dig Dis Sci; 2019 Mar; 64(3):823-831. PubMed ID: 30465175
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Little necessity of acid inhibition against proton pump inhibitor rebound effects and prior helicobacter pylori eradication therapy in gastric ulcer patients: a randomized prospective study.
    Wada Y; Ito M; Takata S; Kitamura S; Takamura A; Tatsugami M; Imagawa S; Matsumoto Y; Tanaka S; Yoshihara M; Chayama K
    Hepatogastroenterology; 2009; 56(91-92):624-8. PubMed ID: 19621668
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [Comparison between histamine H2-blocker and proton pump inhibitor on the effects of initial treatment in reflux esophagitis].
    Harasawa S
    Nihon Rinsho; 2000 Sep; 58(9):1847-52. PubMed ID: 11004814
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Effect of proton pomp inhibitor (PPI : Rabeprazole) on reflux esophagitis after endoscopic injection sclerotherapy (EIS), a randomized control study (24 hour-pH monitoring).
    Akahoshi T; Kawanaka H; Tomikawa M; Saeki H; Uchiyama H; Ikeda T; Shirabe K; Hashizume M; Maehara Y
    Fukuoka Igaku Zasshi; 2013 Dec; 104(12):483-9. PubMed ID: 24693675
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Clinically distinct characteristics in patients younger than 40 years old with non-cardiac chest pain.
    Ko SY; Kim SI; Kim JH; Lee JH; Lee KJ; Hong SN; Lee SY; Sung IK; Park HS; Shim CS
    J Gastroenterol Hepatol; 2012 Sep; 27(9):1484-9. PubMed ID: 22554344
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Impairment of salivary epidermal growth factor secretory response to esophageal mechanical and chemical stimulation in patients with reflux esophagitis.
    Rourk RM; Namiot Z; Sarosiek J; Yu Z; McCallum RW
    Am J Gastroenterol; 1994 Feb; 89(2):237-44. PubMed ID: 8304310
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Rapid metabolizer genotype of CYP2C19 is a risk factor of being refractory to proton pump inhibitor therapy for reflux esophagitis.
    Ichikawa H; Sugimoto M; Sugimoto K; Andoh A; Furuta T
    J Gastroenterol Hepatol; 2016 Apr; 31(4):716-26. PubMed ID: 26580676
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.